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RELEVANCE OF VACCINATION
Anti-cytokine therapy associated with immunosuppressive drugs has demonstrated high efficiency
in treatment of several autoimmune diseases, including rheumatoid arthritis (RA). Current
treatments approved for use in patients are targeting inflammatory cytokines TNF-α, IL-1, or IL-6
and more drugs are undergoing clinical evaluation (Semerano et al., 2016a).
Three types of cytokine inhibitors had been developed in RA. The great majority of them
is constituted by monoclonal antibodies (mAbs) directed against the cytokine or its receptor.
A second category is based on recombinant proteins combining soluble receptors of cytokine
stabilized by the Fc domain of IgG1 antibodies. A third type of anti-cytokine drugs is constituted
by recombinant receptor antagonist that binds to receptor without induction of signaling.
One common feature of these inhibitors is their high interaction with the cytokine or its receptor
that could induce excessive inhibition and some drawback for development. A common side
effect is the production, after treatment, of anti-drug antibodies that result in frequent primary or
secondary resistance to the treatment. In addition all these drugs have limited effect in the majority
of cases; for instance in rheumatoid arthritis, targeted treatments induce 6-month remission in 25–
30% patients, and a response different of remission in 50% cases. Partial resistance represents, in
the first 6 months, 70% of patients. Furthermore, available anti-cytokine drugs are expensive and
need frequent long-term administration.
In this context, a novel type of anti-cytokine drugs based on vaccination is emerging (Semerano
et al., 2012). In this case, therapeutic antibodies are produced by the individual itself. This approach
has the advantage to generate antibodies that are well-tolerated because of the absence of xenogenic
epitopes.
The saga of anti-TNF-α vaccination recapitulates the different steps of such strategy. Several
vaccination approaches were conducted in parallel to develop a vaccine against TNF-α. In order to
induce a B cell response, DNA vaccination, introduction of a foreign Th cell epitope and coupling
TNF-α (or peptides of TNF-α) with carrier proteins were developed in animal models of RA.
A vaccine (TNF-K) constituted by coupling human TNF-α to the carrier protein KLH (keyhole
limpet hemocyanin) was studied extensively in animal models of arthritis and in several clinical
trials. TNF-K vaccine induced the generation of anti-human TNF-α antibodies that didn’t cross
react with mouse TNF-α. Transgenic mice expressing human TNF-α (TTG mice) were a suitable
model of arthritis to evaluate the efficacy of TNF-K vaccine. In this model, TNF-K vaccine resulted
in the production of anti-TNF-α neutralizing antibodies that protected mice against established
arthritis (Le Buanec et al., 2006). Anti-TNF-α antibody production was reversible and could not
be stimulated by TNF-α administration, as this approach did not induce any cellular-mediated
immunity against TNF-α. Therapeutic antibody production was not altered by methotrexate
co-administration and the protective effect was correlated with the levels of anti-TNF-α antibody
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production in sera of vaccinated mice. TNF-K efficacy was
compared to infliximab in TTG mice and showed a delay
before arthritis inhibition linked to the induction of therapeutic
antibodies. This delay did not induce significant alterations of the
paws versus infliximab-treated mice, and could not be reduced
by simultaneous administration of infliximab in mice during
TNF-K vaccination. Indeed, co-administration of TNF-K and
infliximab led to a lower response to the vaccine, probably
due to epitope masking: TNF-K being constituted with the full
human cytokine, infliximab could recognize TNF-α, and increase
the clearance of the vaccine. Experiments in animal models of
Listeria monocytogenes and Mycobacterium tuberculosis recently
shown that mice vaccinated with a TNF conjugate did not
develop a hypersensitivity to these infections (Assier et al.,
2016). A first clinical trial (phase IIa) was conducted with RA
patients who previously experienced secondary failure of TNF-
α inhibitors. Several doses of TNF-K and different schedules of
administration were used in order to give rise to therapeutic
anti-TNF-α antibodies (Durez et al., 2014). TNF-K vaccine
was well tolerated and this first trial held promising clinical
improvements. However, a second clinical trial (phase IIB/II)
conducted with a larger panel of RA patients did not reach
significant therapeutic benefits. This failure could be due to the
absence of detection of neutralizing anti-TNF-α antibodies in
sera of patients.
Similarly to anti-TNF studies, several anti-cytokine
vaccination approaches were developed in autoimmune
models against different cytokines including IL-1β (Table 1).
These vaccines were composed either with entire cytokine or
peptide of cytokine, linked to various carrier proteins (KLH, VLP,
Ova, DTT). The use of the full cytokine to compose a vaccine
presents some limitations. The cost of recombinant purified
cytokines is high and their use induces a polyclonal antibody
response against all exposed epitopes. Among these antibodies,
only a variable proportion will exert neutralizing capacities and
there is a potential risk of unwanted reaction against a shared
epitope.
The use of peptide of cytokine allows limiting antibody
generation to selected epitopes. In return, the conformation and
the peptidic sequence of the cytokine that interact with the
receptor have to be determined. Peptides are often selected in
interacting zone of cytokine with its receptor in order to block
this interaction. Beyond this highest potential selectivity, the
cost of peptides is lower and could lead to similar protections
than its entire cytokine counterpart. In this sense, VEGF
neutralization by both vaccinal approaches was studied in the
collagen-induced arthritis (CIA) model. Vaccines were either
constituted by the full length mouse VEGF-A or a peptide
(Vpep1) selected in the sequence of VEGF-A, linked to the carrier
protein KLH. Vpep1 was chosen for its potential interaction with
the VEGF-A co-receptor Neuropilin-1, implied in pathologic
angiogenesis. Both types of VEGF vaccines led to the production
of anti-VEGF polyclonal neutralizing antibodies. Clinical and
histological scores of inflammation and destruction were reduced
as well as synovial vascularization (Semerano et al., 2016b). Thus,
restraining antibody response to a single peptide sequence with a
peptide vaccine could protect immunized mice from arthritis.
The use of peptides of cytokine could be also an asset when
cytokine are composed of two chains that could be shared
with other cytokines. A vaccinal approach against IL-23 was
conducted with peptides chosen in the IL-23p19 subunit. IL-
23 is important for the generation of Th17 lymphocytes that
are implied in autoimmune diseases. IL-23 is constituted by
the IL-12p40 subunit, shared with IL-12, and the specific IL-
23p19 subunit. Because IL-12 and IL-23 could have opposite
effects in autoimmune models, it was of great importance to
inhibit selectively IL-23. In this context, two different teams
have conducted experiments in CIA and colitis models. The first
vaccine constituted by IL-23p19 peptides linked to KLH was
protective in CIA model, whereas the second constituted by IL-
23p19 peptides fused to hepatitis B core antigen was protective in
colitis.
TARGETING IL-1 IN CHRONIC DISEASES
IL-1 is a major inflammatory cytokine that act at the systemic
and local levels (Cavalli and Dinarello, 2015). IL-1 is encoded
by two distinct genes giving rise to two related but functionally
distinct proteins: IL-1α and IL-1β that interact with two IL-1
receptors. IL-1R2, as a decoy receptor, binds to IL-1 but does
not transmit a signal. Signaling is assumed by IL-1R1 that is
expressed on the surface of most cell types. IL-1α and IL-1β
are primarily expressed as precursors. IL-1α precursor could be
release from necrotic cells in a fully active form. Thus, IL-1α acts
as an alarmin and could induce sterile inflammation. By contrast,
IL-1β precursor is inactive and need to be cleaved to become
active. Several enzymes are implied, as proteinase-3 and elastase
from neutrophils or caspase-1 from hematopoietic cells. In other
cells, caspase-1 exists as a pro-enzyme that needs to be cleaved
by amacromolecular complex named the inflammasome. NLRP3
(also known as cryopyrin) is one of the major component of
inflammasome.Mutations leading to a gain of function of NLRP3
protein are associated with high amounts of IL-1β secretion and
autoinflammatory diseases.
In brief, IL-1α is expressed locally, whereas IL-1β is expressed
at the systemic level and in inflamed sites as synovial fluids
in rheumatoid arthritis or gouty arthritis (McInnes and Schett,
2007; Richette and Bardin, 2010). IL-1α and IL-1β binding could
be limited by the naturally occurring inhibitor IL-1 receptor
antagonist (IL-1Ra). IL-1Ra can bind to IL-1 receptor with
greater affinity than either IL-1α or IL-1β. A recombinant version
of IL-1Ra (anakinra) was developed, but its therapeutic use is
limited by its short-lived effect leading to frequent injections to
the patient. Two other IL-1 blockers were developed and present
lower clearance rates. Rilonacept is a soluble decoy receptor that
inhibits primarily IL-1β, but also IL-1α, and canakinumab is a
monoclonal antibody that neutralizes specifically IL-1β.
It was suggested that specific targeting of IL-1β, may
be beneficial over systemic IL-1 blockade. As an example,
canakinumab was effective for the treatment of acute gouty
arthritis, whereas rilonacept was not. In animal models, several
studies targeting IL-1α and IL-1β by a vaccinal approach
reinforce this hypothesis. Vaccines were obtained by linking
mouse or human IL-1 cytokines to Virus Like Particles (VLPs).
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TABLE 1 | Applications of anti-cytokine vaccinations in autoimmune diseases.
Cytokine target Product Diseases Animal species References Clinical trial
mIL-1β Mouse IL-1β peptides/KLH Arthritis Mouse Bertin-Maghit et al., 2005 Pre-clinical
mIL-1 (α and β) Mouse IL-1α/IL-1β/VLP Arthritis Mouse Spohn et al., 2008 Pre-clinical
hIL-1β and mIL-1β Human and murine IL-1β/VLP Type 2 Diabetes Mouse Spohn et al., 2014 Pre-clinical
hIL-1β Human IL-1β/VLP Type 2 Diabetes Human Cavelti-Weder et al., 2016 Phase I
mIL-6 Modified mouse IL-6 Arthritis, MS Mouse Galle et al., 2007 Pre-clinical
Mouse IL-6 peptide/KLH SSc Mouse Desallais et al., 2014 Pre-clinical
Mouse IL-6 peptide/KLH DTH Monkey Desallais et al., 2016 Pre-clinical
hIL-15 Modified human IL-15 Arthritis Monkey Rodríguez-Álvarez et al., 2016 Pre-clinical
mIL-17A Mouse IL-17A/Ova MS Mouse Uyttenhove and Van Snick, 2006 Pre-clinical
Mouse IL-17A/VLP Arthritis, MS Mouse Röhn et al., 2006 Pre-clinical
Mouse IL-17A/VLP Autoimmune
Myocarditis
Mouse Sonderegger et al., 2006 Pre-clinical
mIL-18 Mouse IL-18 plasmid SLE Mouse Bossù et al., 2003 Pre-clinical
mIL-23 Mouse IL-23p19 peptide/KLH Arthritis Mouse Ratsimandresy et al., 2011 Pre-clinical
Mouse IL-23p19 peptide/HBc Ag Chronic Colitis Mouse Guan et al., 2013 Pre-clinical
hIFN-α Human IFN-α/KLH SLE Hum. Transg. Mouse Zagury et al., 2009 Pre-clinical
Human IFN-α/KLH SLE Hum. Transg. Mouse Mathian et al., 2011 Pre-clinical
Human IFN-α/KLH SLE Human Lauwerys et al., 2013 Phase I/II
Human IFN-α/KLH SLE Human Ducreux et al., 2016 Phase I/II
hTNF-α Human TNF-α/KLH Arthritis Hum. Transg. Mouse Le Buanec et al., 2006 Pre-clinical
Arthritis Hum. Transg. Mouse Delavallée et al., 2008 Pre-clinical
Arthritis Hum. Transg. Mouse Biton et al., 2011 Pre-clinical
Arthritis Mouse Assier et al., 2012 Pre-clinical
Arthritis Hum. Transg. Mouse Semerano et al., 2013 Pre-clinical
Arthritis Human Durez et al., 2014 Phase IIa
mTNF-α Modified mouse TNF-α Arthritis, Cachexia Mouse Dalum et al., 1999 Pre-clinical
Human TNF-α plasmid Arthritis Mouse Shen et al., 2007 Pre-clinical
Mouse TNF-α peptide/VLP Arthritis Mouse Chackerian et al., 2001 Pre-clinical
Mouse TNF-α/TNF-α peptide/VLP Arthritis, Infections Mouse Spohn et al., 2007 Pre-clinical
Mouse TNF-α peptide/KLH Septic shock Mouse Capini et al., 2004 Pre-clinical
Mouse TNF-α peptide/KLH Arthritis Mouse Sun et al., 2016 Pre-clinical
Mouse TNF-α peptide/DTT Arthritis Mouse Zhang et al., 2016 Pre-clinical
rTNF-α Rat TNF-α plasmid Arthritis Rat Wildbaum et al., 2000 Pre-clinical
mVEGF-A Mouse VEGF/VEGF peptide/KLH Arthritis Mouse Semerano et al., 2016b Pre-clinical
DTH, delayed-type hypersensitivity; DTT, transmembrane domain of diphtheria toxin; MS, multiple sclerosis; HBc Ag, hepatitis B core antigen; KLH, keyhole limpet hemocyanin; SLE,
systemic lupus erythematosus; SSc, systemic sclerosis; VLP, virus-like particles.
These compounds led to high production of anti-IL-1α or anti-
IL-1β neutralizing antibodies by vaccinated mice. In the CIA
model, both type of vaccines conduct to a higher protection
against arthritis than daily administration of mouse IL-1Ra. In
a second model of arthritis, the Collagen Antibody-Induced
Arthritis model (CAIA), immunization with the IL-1β vaccine
protects strongly against arthritis, whereas anti-IL-1α vaccine
has no effect (Spohn et al., 2008). IL-1β vaccine was shown
to be also effective in a type 2 diabetes model, and its human
counterpart was well tolerated in a phase I clinical trial in patients
with type 2 diabetes (Cavelti-Weder et al., 2016). In another
study, IL-1β was specifically targeted by vaccines constituted
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by peptides of IL-1β linked to KLH. Peptide sequences were
chosen in regions interacting with the receptor and led to
the generation of neutralizing anti-IL-1β antibodies. One IL-
1β vaccine showed a protective effect in the CIA model on
clinical and histological signs of inflammation (Bertin-Maghit
et al., 2005). Thus, selective inhibition of IL-1β gave promising
results and could be achieved with a peptide-based vaccine.
However, targeting IL-1 or its receptor remains an unresolved
issue, with contrasting animal and in vitro data arguing in
favor of either specific cytokine or receptor blockade, but
no conclusion that is relevant to the clinical use of these
agents.
CANDIDATES FOR A VACCINE TARGETING
IL-1
The best candidates are chronic diseases with flares, IL-1
dependent, and showing some improvement in previous clinical
trials with currently used anti-IL-1 treatments. The low cost
of development could allow treatments of patients in Southern
countries, where access to healthcare is a concern for most of
people. Research on vaccination targeting IL-1β is still ongoing.
Preclinical studies with a peptide-based vaccine targeting IL-1β
are currently focused on carrier protein and adjuvant, and clinical
studies are planned. The use of vaccination targeting IL-1 extends
now from initial rheumatic diseases, such as RA and crystal-
induced arthritis (such as gout or acute chondrocalcinosis), to
autoinflammatory diseases, such as systemic juvenile idiopathic
arthritis (JIA), cryopyrin-associated periodic syndromes (CAPS),
and familial Mediterranean fever (FMF). IL-1 inhibitors are
also promising in two highly prevalent inflammatory diseases,
encountered as co-morbidities in patients with rheumatic
diseases, namely arteriosclerosis and type 2 diabetes.
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